Physician profile
Letitia M Hazel
NPI 1588641880
$781.64
in general payments reported to CMS, 2019-2025
11 companies · $46.84 in 2025
The $46.84 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.04 · 2020: $22.73 · 2023: $237 · 2024: $423 · 2025: $46.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $706.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $139.89 | 2019-2024 | Perseris, Sublocade |
| Neurocrine Biosciences, INC. | $128.31 | 2023-2025 | Ingrezza |
| Braeburn INC. | $117.23 | 2024-2025 | Brixadi |
| Janssen Pharmaceuticals, INC | $116.24 | 2023-2024 | Invega Sustenna |
| Alkermes, INC. | $85.76 | 2023-2024 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $80.70 | 2023-2024 | Austedo Xr, Uzedy |
| Corium, LLC | $31.83 | 2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $29.37 | 2024 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $18.27 | 2024 | Auvelity |
| Abbvie INC. | $17.64 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $16.40 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Letitia Hazel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.